By increasing Sirt1 and turning on the AMPK pathway, miR-122 inhibition protects hepatocytes from lipid metabolic diseases such as NAFLD and inhibits lipogenesis [76]. The gene discussed is SIRT1; the disease is metabolic dysfunction-associated steatotic liver disease.